Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Giovanni Pisa"'
Publikováno v:
Haematologica, Vol 100, Iss 11 (2015)
Low molecular weight heparins have demonstrated superiority over coumarins in the extended treatment of cancer-associated thrombosis and are recommended as first-line therapy in clinical guidelines. Non-vitamin K oral antagonists are yet to be evalua
Externí odkaz:
https://doaj.org/article/625cd11b7734494aa6c0fbaa7715ac66
Publikováno v:
Haematologica. 100:1486-1492
Low molecular weight heparins have demonstrated superiority over coumarins in the extended treatment of cancer-associated thrombosis and are recommended as first-line therapy in clinical guidelines. Non-vitamin K oral antagonists are yet to be evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18cfc50fa53bae4540213bce7a2224eb
https://doi.org/10.3324/haematol.2015.127126
https://doi.org/10.3324/haematol.2015.127126
Publikováno v:
The Patient - Patient-Centered Outcomes Research. 6:93-101
In the management of chronic obstructive pulmonary disease (COPD), knowledge of disease attributes and preferences that are important to patients is crucial. This knowledge may support drug development and optimization of COPD management strategies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abd4ccc207df053f7ef9c40b056f36dd
https://doi.org/10.1007/s40271-013-0007-2
https://doi.org/10.1007/s40271-013-0007-2
Critical limb ischemia (CLI) has a significant impact on patients' quality of life (QoL). Despite cost utility evaluations being required by different authorities, data on patient health preferences and utilities for CLI are scarce. Hence, the object
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de02740abd0e303a2e33f3be138497c3
https://europepmc.org/articles/PMC3578621/
https://europepmc.org/articles/PMC3578621/
Publikováno v:
Patient preference and adherence
Giovanni Pisa,1 Florian Eichmann,1 Stephan Hupfer21Kantar Health GmbH, Munich, Germany; 2Novartis Pharma GmbH, Nuernberg, GermanyAim: The course of heart failure (HF) is characterized by frequent hospitalizations, a high mortality rate, as well as a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21400cb82ae11e0f1192d8c4b88ac2eb
https://doi.org/10.2147/ppa.s88167
https://doi.org/10.2147/ppa.s88167